TNFRSF4 and neoplasm: Given the ongoing clinical trial testing CpG+OX40 in patients with advanced or metastatic solid tumors, adding RT to the in situ vaccine CpG+OX40 to improve the adaptive anti-tumor immune response in patients warrants further investigation.